Specify a stock or a cryptocurrency in the search bar to get a summary
Hemogenyx Pharmaceuticals PLC
5HUHemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom. Address: 60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 5HU
Dividend Analytics 5HU
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 5HU
Stock Valuation 5HU
Financials 5HU
Results | 2019 | Dynamics |